Results 61 to 70 of about 8,174 (197)
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin +13 more
doaj +1 more source
Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka +12 more
wiley +1 more source
Gut and Liver, 2019 Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee +11 more
doaj +1 more source
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
New Microbes and New Infections, 2021 Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M. Shabani +3 more
doaj +1 more source
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]
, 2018 [Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio +20 more
core +2 more sources
Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li +3 more
wiley +1 more source
Vaccines, 2023 The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation.
Sneha Bansode +10 more
doaj +1 more source
Possible acute rejection associated with the use of the new antihepatitis C virus medications
Avicenna Journal of Medicine, 2019 Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant.
Khaled Ar Karkout +4 more
doaj +1 more source
Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy [PDF]
, 2014 Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors.
Carpio Pedroza, Juan Carlos +10 more
core +1 more source
International Journal of Hepatology, Volume 2026, Issue 1, 2026.Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara +11 more
wiley +1 more source